logo-loader
HealthPharma & Biotech
CymaBay Therapeutics

Shares of CymaBay Therapeutics gain after study signals Seladelpar treatment shows 'efficacy'

The company now expects drug to advance to Phase 3 study

Assorted pills on table
The shares gained 11% on the study news

Shares of CymaBay Therapeutics Inc. (NASDAQ:CBAY) rose after the company said a study of its Seladelpar treatment for an autoimmune disease of the liver showed “compelling efficacy and tolerability.”

The stock advanced 11% to US$13.44.

The results from the Phase 2 study “support the potential for improved efficacy and better tolerability over existing second-line therapy,” the company said in a statement. CymaBay now expects the treatment to advance to Phase 3 in the second half of the year.

 

Quick facts: CymaBay Therapeutics

Price: $5.61

Market: NASDAQ
Market Cap: $385.41 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: TrueLeaf continues to see a bright road ahead for cannabis...

Trueleaf (CSE: MJ-OTCQX: TRLFF) Executive Vice President Tenzin Khangsar joined Steve Darling from Proactive Vancouver to talk about a big name in the cannabis world moving into the cannabis pet space. Khangsar also told Proactive about their push for cannabis legal for pets in Canada. 

4 hours, 11 minutes ago

2 min read